V
VTRS
Viatris Inc Ord Shs
16.27
-0.07-0.43%After Hours: 16.48 +0.21 +1.29%19:57 07/10 EDT
OPEN/PREV CLOSE16.34/16.34
TODAY RANGE15.95-16.37
VOL7.93M
MARKET CAP18.95B
52 WEEK RANGE8.30-17.40
AVG VOL (3M)11.12M
% TURNOVER0.68%
TURNOVER--
P/E (TTM)-62.8428
% RANGE2.51%
EPS(TTM)-0.2589
P/E(FORWARD)108.92
P/B1.293
BVPS12.59
DIVIDEND0.4800
P/S1.310
BETA--
DIV YIELD2.95%
FREE FLOAT MKT CAP18.89B
SHARES OUTSTANDING1.16B
NEXT EARNINGS08/05-08/10
FREE FLOAT1.16B
LOT SIZE1
EX-DATE05/22/2026
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS)
Simply Wall St·07/03 21:32
Viatris (VTRS) Could Be 57% Undervalued As Phase 3 Kidney Data Lands
TipRanks·07/01 21:10
Viatris Secures New ¥40 Billion Term Loan Facility
Reuters·07/01 20:24
VIATRIS - SECURES ¥40 BLN SENIOR UNSECURED TERM LOAN FACILITY - SEC FILING
Simply Wall St·07/01 11:37
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205
PR Newswire·07/01 10:59
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
NASDAQ·07/01 10:00
Biotech Stocks Facing FDA Decision In July 2026
NASDAQ·06/30 12:54
Theravance Stock Down 3% After Zymeworks Announces Buyout
Seeking Alpha·06/29 14:57
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN
NASDAQ·06/29 11:53
Viatris Reports Positive Results From Phase 3 IgAN Trial In Japan
Benzinga·06/29 11:46
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
TipRanks·06/29 11:05
Viatris announces VR-205 trial achieves primary endpoint